

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy in Surgically Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology and Canadian Society of Oncology and Palliative Care Ontario Clinical Practice Guideline Update

Journal of Clinical Oncology

35, 2960-2974

DOI: 10.1200/jco.2017.72.4401

Citation Report

#	ARTICLE	IF	CITATIONS
1	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479.	0.7	11
2	What is the optimal adjuvant therapy for T3N0 lung cancer invading the chest wall?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4233-4235.	0.6	0
3	Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2628-2631.	0.4	10
4	Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 543-549.	0.5	15
5	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
6	One size does not fit all: Nuances in postoperative non-small cell lung cancer management. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 370-373.	0.4	2
7	Long non-coding RNA linc01433 promotes migration and invasion in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 589-597.	0.8	19
8	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-III A (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	5.1	436
9	Stereotactic Body Radiotherapy for Early-Stage Non-small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 710-719.	0.8	127
10	Liquid biopsy for lung cancer early detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S882-S897.	0.6	93
11	Meet the new boss: lung cancer staging. <i>Journal of Thoracic Disease</i> , 2018, 10, 1329-1331.	0.6	1
12	Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. <i>Journal of Thoracic Disease</i> , 2018, 10, 1364-1369.	0.6	6
13	Invited letter to the editor on the editorial on "Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy". <i>Journal of Thoracic Disease</i> , 2018, 10, S2083-S2085.	0.6	1
14	Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S171-S175.	1.3	1
15	Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer—the more specific, the better?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3961-S3964.	0.6	1
16	The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β -tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 21-29.	0.4	3
17	Research progress of the clinicopathologic features of lung adenosquamous carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7011-7017.	1.0	12
18	Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 126, 64-71.	0.9	39

#	ARTICLE	IF	CITATIONS
19	The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 379-387.	0.8	26
20	Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. <i>Cancer Science</i> , 2018, 109, 3326-3335.	1.7	32
21	Adenosquamous carcinoma of the lung. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4829-4835.	1.0	70
22	What pharmacotherapeutics should one use for early stage non-small cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1403-1406.	0.9	4
23	Unsuspected N2-positive non-small cell lung cancer after complete resection: is there a place for multimodal adjuvant therapy?. <i>AME Medical Journal</i> , 0, 3, 23-23.	0.4	0
24	Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer. <i>EBioMedicine</i> , 2018, 33, 16-17.	2.7	4
25	Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database. <i>Cancer Medicine</i> , 2018, 7, 4354-4360.	1.3	18
26	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	2.6	15
27	A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 7-13.	0.9	36
28	Check the Reports and Check the Brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 711-712.	0.4	0
29	The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 712-713.	0.4	0
30	KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e153-e155.	0.5	2
31	Thoracic Postoperative Radiation Therapy: To Treat or Not to Treat?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 710.	0.4	4
32	A Reaction-Based Fluorescent Probe for Imaging of Native Hypochlorous Acid. <i>Chemistry - an Asian Journal</i> , 2019, 14, 3893-3897.	1.7	13
33	Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1750.	1.7	29
34	<p>>Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations</p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8779-8787.	1.0	5
35	Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 221.	1.8	26
36	Retrospective study of efficacy of adjuvant chemotherapy using tegafur-uracil in patients with non-small cell lung cancer with primary tumor size of 4.1-5.0 cm. <i>Journal of Thoracic Disease</i> , 2019, 11, 3103-3111.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	24
38	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1683-1689.	0.7	6
39	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2392-2400.	0.7	12
40	Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2019, 133, 75-82.	0.9	21
41	<p>Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2677-2690.	0.9	10
42	Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients. <i>Frontiers in Genetics</i> , 2019, 10, 390.	1.1	68
43	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159
44	<p>miR-600 inhibits lung cancer via downregulating the expression of METTL3<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1177-1187.	0.9	107
45	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
46	<p>Low Expression of ASK1-Interacting Protein-1 Is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early Stage Non-Small Cell Lung Cancer<p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10739-10747.	1.0	1
47	Clinical characteristics and medical service utilization of lung cancer in China, 2005â€“2014: Overall design and results from a multicenter retrospective epidemiologic survey. <i>Lung Cancer</i> , 2019, 128, 91-100.	0.9	81
48	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (â‰¤2 cm) Lung Adenocarcinoma: An International Cohort Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 72-86.	0.5	41
49	Collective cancer invasion forms an integrin-dependent radioresistant niche. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	55
50	Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2020, 109, 927-937.	0.7	4
51	Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 801-807.	1.2	9
52	Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORC 0503. <i>Lung Cancer</i> , 2020, 141, 32-36.	0.9	9
53	Efficient Lung Nodule Classification Using Transferable Texture Convolutional Neural Network. <i>IEEE Access</i> , 2020, 8, 175859-175870.	2.6	41
54	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage IIâ€“IIIa (N1â€“N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. <i>Lung Cancer</i> , 2020, 150, 164-171.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 263.	0.8	6
56	LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. <i>Theranostics</i> , 2020, 10, 7527-7544.	4.6	26
57	The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 496-503.	0.6	2
58	Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1288-1288.	0.7	4
59	First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. <i>Journal of Thoracic Disease</i> , 2020, 12, 3764-3773.	0.6	8
60	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 236-265.	0.2	9
61	Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. <i>JAMA Oncology</i> , 2020, 6, 1741.	3.4	55
62	Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1112-1123.	1.3	27
63	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	13.9	1,042
64	ZIC2 promotes cancer stem cell traits via up-regulating OCT4 expression in lung adenocarcinoma cells. <i>Journal of Cancer</i> , 2020, 11, 6070-6080.	1.2	11
65	Risk Prediction for Locoregional Recurrence in Epidermal Growth Factor Receptor-Mutant Stage III-pN2 Lung Adenocarcinoma after Complete Resection: A Multi-center Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 6114-6121.	1.2	2
66	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 109.	1.8	10
67	Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. <i>Journal of Translational Medicine</i> , 2020, 18, 320.	1.8	7
68	Thymosin β 10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. <i>Respiratory Research</i> , 2020, 21, 328.	1.4	18
69	A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707). <i>JTCVS Open</i> , 2020, 4, 90-102.	0.2	14
70	Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. <i>Frontiers in Oncology</i> , 2020, 10, 571.	1.3	26
71	Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. <i>Histopathology</i> , 2020, 77, 55-66.	1.6	13
72	circ_0007385 served as competing endogenous miRNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. <i>Thoracic Cancer</i> , 2020, 11, 2196-2208.	0.8	34

#	ARTICLE	IF	CITATIONS
73	Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types. <i>Bioinformatics</i> , 2020, 36, 5037-5044.	1.8	1
74	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290.	13.7	213
75	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	1.8	7
76	A review on <scp>RNAi</scp> therapy for <scp>NSCLC</scp>: Opportunities and challenges. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1677.	3.3	15
77	Management guidelines for stage III non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103144.	2.0	17
78	Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines. <i>Integrative Medicine Research</i> , 2021, 10, 100452.	0.7	12
79	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	0.8	159
80	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.4	10
81	Influence of adjuvant chemotherapy on survival for patients with stage <scp>IB</scp> and <scp>IIA</scp> non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 30-39.	0.8	13
82	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	4
83	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Non-small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 325-332.	1.5	7
84	Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected <scp>IIIA</scp>/<scp>N2</scp> non-small cell lung cancer: A population-based study. <i>Thoracic Cancer</i> , 2021, 12, 760-767.	0.8	8
85	Prognostic utility of inflammation-based biomarkers, neutrophil-lymphocyte ratio and change in neutrophil-lymphocyte ratio, in surgically resected lung cancers. <i>Annals of Thoracic Medicine</i> , 2021, 16, 148.	0.7	5
86	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. <i>Theranostics</i> , 2021, 11, 5650-5674.	4.6	76
87	Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-small-Cell Lung Cancer?. <i>JCO Precision Oncology</i> , 2021, 5, 408-414.	1.5	7
88	Is Adjuvant Radiochemotherapy Always Mandatory in Patients with Resected N2 Non-Small Cell Lung Cancer?. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, , .	0.4	0
89	Osimertinib in <i>EGFR</i>-Mutated Lung Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 675-676.	13.9	8
90	Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636913.	1.8	7

#	ARTICLE	IF	CITATIONS
91	Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 619376.	1.3	3
92	Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. <i>BMC Cancer</i> , 2021, 21, 215.	1.1	3
93	The role of <sc>EGFR-TKIs</sc> as adjuvant therapy in <sc>EGFR mutation-positive early-stage NSCLC</sc>: A meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1084-1095.	0.8	12
94	Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	2
95	Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS-mitochondrial fission-mitophagy axis. <i>Molecular Oncology</i> , 2021, 15, 2084-2105.	2.1	76
96	Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100161.	0.6	2
97	Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3699-3707.	1.2	6
98	Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center. <i>Medical Science Monitor</i> , 2021, 27, e930738.	0.5	5
99	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
100	Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. <i>Cancers</i> , 2021, 13, 1812.	1.7	1
101	Drug Regimen for Patients after a Pneumonectomy. <i>Journal of Respiration</i> , 2021, 1, 114-134.	0.4	0
102	Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	12.5	152
103	New developments in locally advanced nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200227.	3.0	9
104	Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes. <i>Journal of Thoracic Oncology</i> , 2021, 16, 774-783.	0.5	10
105	Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. <i>Nature Communications</i> , 2021, 12, 2581.	5.8	103
106	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. <i>Molecular Therapy</i> , 2021, 29, 2963-2978.	3.7	9
107	Circulating CD15 ⁺ LOX-1 ⁺ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small-cell lung cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14317.	0.8	4
108	A comparison on the use of Perlin-noise and Gaussian noise based augmentation on X-ray classification of lung cancer patient. <i>Journal of Physics: Conference Series</i> , 2021, 1951, 012064.	0.3	5

#	ARTICLE	IF	CITATIONS
109	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	2.1	9
110	Nomogram to Predict Cancer Specific Survival in Patients with Pathological Stage IA Non-small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 1040-1048.	0.4	8
111	Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges. Cancers, 2021, 13, 3759.	1.7	14
112	Commentary: Adjuvant therapy in resected T1 2N0 non-small cell lung cancer: Surgeons should lead. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	0
113	Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer. Journal of Oncology, 2021, 2021, 1-10.	0.6	9
114	FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research, 2021, 27, 6638-6643.	3.2	35
115	Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations. Lung Cancer, 2021, 158, 60-73.	0.9	6
116	The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database. Lung Cancer, 2021, 158, 47-54.	0.9	7
117	Association of postoperative recurrence with radiological and clinicopathological features in patients with stage IA-IIA lung adenocarcinoma. European Journal of Radiology, 2021, 141, 109802.	1.2	2
118	Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion. Chest, 2021, 160, 754-764.	0.4	13
119	Development of Nomograms for Predicting Lymph Node Metastasis and Distant Metastasis in Newly Diagnosed T1-2 Non-Small Cell Lung Cancer: A Population-Based Analysis. Frontiers in Oncology, 2021, 11, 683282.	1.3	8
120	Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 693353.	1.3	6
121	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 2021, 162, 42-53.	0.9	22
122	Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. Radiation Oncology, 2021, 16, 184.	1.2	2
123	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Translational Oncology, 2021, 14, 101179.	1.7	11
124	The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung adenocarcinoma has on T-stage and treatment. Annals of Diagnostic Pathology, 2021, 54, 151799.	0.6	2
125	Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States. Journal of Thoracic Oncology, 2021, 16, 1663-1671.	0.5	7
126	A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 149-159.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials. <i>Oncology Research and Treatment</i> , 2021, 44, 344-353.	0.8	7
128	Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109896.	2.5	28
129	Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 211-222.	0.8	18
130	Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097814.	1.4	26
131	Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. <i>Annals of Translational Medicine</i> , 2019, 7, 42-42.	0.7	9
132	Construction of a competing endogenous RNA network using differentially expressed lncRNAs, miRNAs and mRNAs in non-small cell lung cancer. <i>Oncology Reports</i> , 2019, 42, 2402-2415.	1.2	16
133	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16
134	Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non-Small Cell Lung Cancer: Analysis of the SEER Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 718-727.	2.3	19
135	Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. <i>Vaccines</i> , 2021, 9, 1122.	2.1	18
136	Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story. <i>World Journal of Clinical Oncology</i> , 2021, 12, 833-844.	0.9	1
137	Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e171-e172.	1.1	1
140	A new method for accurately localizing and resecting pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2020, 12, 4973-4984.	0.6	10
141	Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1613-1613.	0.7	0
142	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	0.5	89
144	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100084.	0.6	2
146	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 163-174.	0.3	4
147	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib. <i>Lipids in Health and Disease</i> , 2021, 20, 165.	1.2	6
148	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.	0.6	11

#	ARTICLE	IF	CITATIONS
149	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	1.4	6
150	Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study. <i>Modern Pathology</i> , 2022, 35, 749-756.	2.9	27
151	CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 341.	1.0	6
152	Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 556-566.	0.8	17
153	Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-555.	0.8	84
154	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	5.1	123
155	A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 75-86.	1.3	5
156	A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 1-17.	0.6	0
157	BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma. <i>Antioxidants</i> , 2022, 11, 114.	2.2	3
158	Prognostic evaluation of the proposed residual tumor classification in a Chinese non-small cell lung cancer population. <i>Journal of Surgical Oncology</i> , 2022, 125, 1061-1070.	0.8	3
159	A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 4243-4253.	1.0	6
160	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	4.9	31
161	Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2022, 18, 1159-1169.	1.1	6
162	Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 947-955.	0.8	8
163	Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 824.	1.7	2
165	Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large cell neuroendocrine carcinoma. <i>Thoracic Cancer</i> , 2022, 13, 900-912.	0.8	4
166	A Risk Model to Predict the Delivery of Adjuvant Chemotherapy Following Lung Resection in Patients With Pathologically Positive Lymph Nodes. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2023, 35, 387-398.	0.4	3
167	Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. <i>BMC Cancer</i> , 2022, 22, 328.	1.1	16

#	ARTICLE	IF	CITATIONS
168	Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-III A Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1127-1129.	0.8	36
169	Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature. <i>Translational Lung Cancer Research</i> , 2021, 10, 4643-4665.	1.3	7
170	The Independent Prognostic Effect of Lymph Node Dissection on Patients With Stage IA NSCLC With Different T Stages. <i>Frontiers in Surgery</i> , 2021, 8, 798046.	0.6	2
171	Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 1356-1384.	0.8	104
172	Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1587-1602.e5.	0.4	7
173	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1949.	1.7	2
176	Immortal Time Bias-Corrected Effectiveness of Traditional Chinese Medicine in Non-Small Cell Lung Cancer (C-EVID): A Prospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 845613.	1.3	3
177	Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	3
178	Rethinking the Selection of Pathological T-Classification for Non-Small-Cell Lung Cancer in Varying Degrees of Visceral Pleural Invasion: A SEER-Based Study. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	2
179	Malignant Central Airway Obstruction: What's New?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 512-529.	0.8	2
180	Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. <i>Targeted Oncology</i> , 2022, 17, 369-376.	1.7	4
181	A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting. <i>Cancers</i> , 2022, 14, 2971.	1.7	6
182	Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?. <i>ESMO Open</i> , 2022, 7, 100508.	2.0	5
183	SEN1 Aberrance and Its Linkage to Clinical Features, Adjuvant Regimen, and Prognosis in Patients With Surgical Non-small Cell Lung Cancer Receiving Adjuvant Chemotherapy. <i>Frontiers in Surgery</i> , 0, 8, .	0.6	2
184	Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 2695-2707.	1.1	1
185	Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China. <i>Cancer Medicine</i> , 0, , .	1.3	2
186	Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1539.	1.4	2
187	Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 338-347.	1.2	2

#	ARTICLE	IF	CITATIONS
188	Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1775-1782.	0.7	2
189	Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 285-297.	0.8	3
190	Real-world <sc>KINDLE</sc> Latin America subset data on treatment patterns and clinical outcomes in patients with stage <sc>III</sc> non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
191	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
192	Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	1
193	Adjuvant chemotherapy can benefit the survival of stage I lung adenocarcinoma patients with tumour spread through air spaces after resection: Propensity-score matched analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
194	LIBRETTO-432, a phase III study of adjuvant seliperatinib or placebo in stage IB-IIIa <i>RET</i> fusion-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 3133-3141.	1.1	9
195	Berberamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 1297-1317.	2.4	4
196	EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. <i>Lung Cancer</i> , 2022, 173, 58-66.	0.9	5
197	Egfr Mutation Prevalence, Real-World Treatment Patterns, and Outcomes Among Patients with Resected, Early-Stage, Non-Small Cell Lung Cancer in Canada. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
198	The effect of paclitaxel plus carboplatin chemotherapy on subclinical cardiotoxicity in patients with non-small cell lung cancer: A speckle tracking echocardiography-based study. <i>Revista Portuguesa De Cardiologia</i> , 2022, , .	0.2	3
200	Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1809-1822.	1.3	0
202	LncRNA KCNQ1OT1 enhances the radioresistance of lung squamous cell carcinoma by targeting the miR-491-5p/TPX2-RNF2 axis. <i>Journal of Thoracic Disease</i> , 2022, 14, 4081-4095.	0.6	5
203	The Value of Radiotherapy in Patients With Resectable Stage IIIa Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis. <i>Clinical Lung Cancer</i> , 2023, 24, 18-28.	1.1	2
204	A clinical risk model for assessing the survival of patients with stage IA-IIA non-small cell lung cancer after surgery. <i>Journal of Thoracic Disease</i> , 2022, 14, 4285-4296.	0.6	6
205	Adjuvant chemotherapy for completely resected IIA-IIIa non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice. <i>Translational Lung Cancer Research</i> , 2022, 11, 2418-2437.	1.3	2
206	Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. <i>Clinical Lung Cancer</i> , 2023, 24, 260-268.	1.1	7
207	Potential Targets and Mechanisms of <i>Dalbergia odorifera</i> on Treating Lung Adenocarcinoma Explored by Network Pharmacology. <i>International Journal of Pharmacology</i> , 2023, 19, 52-63.	0.1	0

#	ARTICLE	IF	CITATIONS
208	Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
209	Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. <i>Biomarker Research</i> , 2023, 11, .	2.8	8
210	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarHá€like homeobox 2 axis. <i>Anti-Cancer Drugs</i> , 2023, 34, 640-651.	0.7	1
211	Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-III A Noná€Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1830-1840.	0.8	84
212	Preoperative prognostic prediction for stage I lung adenocarcinomas: Impact of the computed tomography features associated with the new histological grading system. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
213	A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
214	Postoperative circulating tumor <scp>DNA</scp> can refine risk stratification in resectable lung cancer: results from a multicenter study. <i>Molecular Oncology</i> , 2023, 17, 825-838.	2.1	0
215	Adjuvant therapies in stages Iá€III epidermal growth factor receptor-mutated lung cancer: current and future perspectives. <i>Translational Lung Cancer Research</i> , 2023, 12, 824-836.	1.3	2
216	Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces. <i>Lung Cancer</i> , 2023, 177, 51-58.	0.9	4
217	Management of papillary thyroid cancer with tracheal invasion and lung cancer: A case report. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
218	Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. <i>EClinicalMedicine</i> , 2023, 57, 101839.	3.2	7
219	Construction of IL-1 signalling pathway correlation model in lung adenocarcinoma and association with immune microenvironment prognosis and immunotherapy: Multi-data validation. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
220	Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. <i>PharmacoEconomics - Open</i> , 0, , .	0.9	1
221	Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 2081.	1.0	0
222	Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6086.	1.8	4
223	Postoperative chemotherapy significantly improves survival of elderly patients with stage <scp>IBá€noná€small cell lung cancer: A populationá€based study. <i>Cancer Medicine</i> , 2023, 12, 11254-11263.	1.3	2
245	Treatment of Stage III Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 147-163.	0.1	0
246	Treatment of Early-Stage (Stage I and II) Non-Small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 123-145.	0.1	0

#	ARTICLE	IF	CITATIONS
253	cal changes associated with peri-parturient period in dairy cows. International Journal of Clinical Oncology, 0, bean breeding: A comprehensive review of speed breeding.	1.0	0